Clinical Trial Update: Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial assessing oxaliplatin with or without nivolumab in combination with trifluridine/tipiracil or 5-fluorouracil for frail patients with advanced, rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma
• Gastric Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Eloxatin (oxaliplatin)
• Lonsurf (trifluridine/tipiracil)
• OPDIVO (nivolumab)

Snippet

Sponsor: UNICANCER | Conditions: Gastric Adenocarcinoma, Esophagus Adenocarcinoma | Phase 2 | Status: RECRUITING